Pharmafile Logo

Therapy Watch launches new tracker covering pulmonary arterial hypertension (PAH)

Therapy Watch Pulmonary Arterial Hypertension (PAH) is launching in the US market, with expansion into other geographies including Europe in 2024.

Patient record form (PRF) insights will be collected via online interviews with a panel of Pulmonologists and Cardiologists who are specialized in the- PMLiVE treatment of PAH.

The new study will delve into a range of topics including the drivers behind treatment decisions, the real-world usage of mono/dual/triple therapy combinations, the treatment pathway and timings, how the physician setting affects treatments prescribed, and impact of new launches on the market dynamics.

Read more here.

This content was provided by Research Partnership

Company Details

 Latest Content from  Research Partnership 

Quantitative specialist joins Research Partnership, London

Global healthcare market research consultancy Research Partnership has appointed Roy Rogers as a Quantitative Director in their UK offices in London

Webcast

Amplifying the patient voice: How to conduct patient research sensitively to uncover emotional insights

Webcast

The power of a good story: Turn your insights into effective storytelling with data visualisation

Article

How will COVID-19 affect uptake of vaccinations against other diseases?

Podcast

Living With Chronic Illness (Series one)

Webcast

China: How pharma can maximize success in this rapidly changing emerging market

Article

Inhale, Exhale: The struggle of living with Severe Asthma and Severe Eosinophilic Asthma

Infographic

Migraine market snapshot

Webcast

Monitoring the impact of COVID-19 on the market access landscape

Live webinar from Singapore

Digital #marcomms: How to evaluate and optimise marketing activities impacted by COVID-19